COVID-19

Remdisivir for COVID-19 to be priced under Rs 5,000 in India

Cipla and Hetero Labs have received approval to sell generic versions of remdesivir, developed by Gilead Sciences Inc, in India

ByIFP Bureau

Updated 24 Jun 2020, 4:38 pm

(Image-Dimitri Karastelev-Unsplash)
(Image-Dimitri Karastelev-Unsplash)

Indian pharmaceutical company Cipla Ltd has announced that its generic version of antiviral drug remdesivir for use in treating COVID-19 patients will be made available under Rs 5,000.

Advertisement

However, the company did not provide details on when the generic version called Cipremi, will be available. 

Cipla and privately held Indian drugmaker Hetero Labs received approval to sell generic versions of remdesivir, developed by Gilead Sciences Inc, in the country on Sunday.

According to reports, remdesivir, which is administered via injection in hospitals, is the first treatment that show improvement in COVID-19 trials.

Advertisement

Countries like the United States, India and South Korea have approved the drug for emergency use in severely ill patients while Japan has given full approval for use of the drug.

Beximco Pharmaceuticals Ltd of Bangladesh was the first company in the world to introduce a generic version of remdesivir in May.

Advertisement

First published:24 Jun 2020, 7:34 am

Tags:

covid-19 drugRemdesivircovid-19 treatment

IFP Bureau

IFP Bureau

IMPHAL, Manipur

Advertisement

Top Stories

Loading data...
Advertisement

IFP Exclusive

Loading data...
Advertisement

Feedback

Have a complaint, a suggestion or just some feedback about our content? Please write to onlineifp@gmail.com and we’ll do our best to address it.